Hcp1-loaded staphylococcal membrane vesicle vaccine protects against acute melioidosis

Burkholderia pseudomallei is the causal agent of melioidosis, a deadly tropical infectious disease that lacks a vaccine. On the basis of the attenuated Staphylococcus aureus RN4220-Δagr (RN), we engineered the RN4220-Δagr/pdhB-hcp1 strain (RN-Hcp1) to generate B. pseudomallei hemolysin-coregulated protein 1 (Hcp1)-loaded membrane vesicles (hcp1MVs). The immunization of BALB/c mice with hcp1MVs mixed with adjuvant by a three-dose regimen increased the serum specific IgG production. The serum levels of inflammatory factors, including TNF-α and IL-6, in hcp1MV-vaccinated mice were comparable with those in PBS-challenged mice. The partial adjuvant effect of staphylococcal MVs was observed with the elevation of specific antibody titer in hcp1MV-vaccinated mice relative to those that received the recombinant Hcp1 protein (rHcp1) or MVs derived from RN strain (ΔagrMVs). The hcp1MVs/adjuvant vaccine protected 70% of mice from lethal B. pseudomallei challenge. Immunization with hcp1MVs only protected 60% of mice, whereas vaccination with rHcp1 or ΔagrMVs conferred no protection. Moreover, mice that received hcp1MVs/adjuvant and hcp1MVs immunization had low serum TNF-α and IL-6 levels and no inflammatory infiltration in comparison with other groups. In addition, all surviving mice in hcp1MVs/adjuvant and hcp1MVs groups exhibited no culturable bacteria in their lungs, livers, and spleens five days postinfection. Overall, our data highlighted a new strategy for developing B. pseudomallei vaccine and showed that Hcp1-incorporated staphylococcal MV is a promising candidate for the prevention of acute melioidosis.

[1]  Jennifer L. Dankmeyer,et al.  Layered and integrated medical countermeasures against Burkholderia pseudomallei infections in C57BL/6 mice , 2022, Frontiers in Microbiology.

[2]  Xiao Zhao,et al.  Nanocarriers based on bacterial membrane materials for cancer vaccine delivery , 2022, Nature Protocols.

[3]  R. Vandenbroucke,et al.  The tremendous biomedical potential of bacterial extracellular vesicles. , 2022, Trends in biotechnology.

[4]  Yifan Rao,et al.  A vancomycin resistance-associated WalK(S221P) mutation attenuates the virulence of vancomycin-intermediate Staphylococcus aureus , 2021, Journal of advanced research.

[5]  Yifan Rao,et al.  Engineered Remolding and Application of Bacterial Membrane Vesicles , 2021, Frontiers in Microbiology.

[6]  J. Lötvall,et al.  Synthetic bacterial vesicles combined with tumour extracellular vesicles as cancer immunotherapy , 2021, Journal of extracellular vesicles.

[7]  A. Torres,et al.  Antigen-specific antibody and polyfunctional T cells generated by respiratory immunization with protective BurkholderiaΔtonBΔhcp1 live attenuated vaccines , 2021, npj Vaccines.

[8]  M. Valvano,et al.  Current Advances in Burkholderia Vaccines Development , 2020, Cells.

[9]  C. Bayliss,et al.  Broad vaccine protection against Neisseria meningitidis using factor H binding protein. , 2020, Vaccine.

[10]  T. Nagakubo,et al.  Cracking Open Bacterial Membrane Vesicles , 2020, Frontiers in Microbiology.

[11]  Ammar Aziz,et al.  Comparative genomics confirms a rare melioidosis human-to-human transmission event and reveals incorrect phylogenomic reconstruction due to polyclonality , 2019, bioRxiv.

[12]  E. Bertherat,et al.  Global burden of melioidosis in 2015: a systematic review and data synthesis. , 2019, The Lancet. Infectious diseases.

[13]  A. Torres,et al.  Evaluation of Burkholderia mallei ΔtonB Δhcp1 (CLH001) as a live attenuated vaccine in murine models of glanders and melioidosis , 2019, PLoS neglected tropical diseases.

[14]  A. Torres,et al.  Novel multi‐component vaccine approaches for Burkholderia pseudomallei , 2019, Clinical and experimental immunology.

[15]  R. Cabeza,et al.  Present and Future , 2008 .

[16]  A. Torres,et al.  Burkholderia pseudomallei ΔtonB Δhcp1 Live Attenuated Vaccine Strain Elicits Full Protective Immunity against Aerosolized Melioidosis Infection , 2019, mSphere.

[17]  B. He,et al.  The autotransporter protein BatA is a protective antigen against lethal aerosol infection with Burkholderia mallei and Burkholderia pseudomallei , 2018, Vaccine: X.

[18]  P. Keim,et al.  Caprine humoral response to Burkholderia pseudomallei antigens during acute melioidosis from aerosol exposure , 2018, bioRxiv.

[19]  I. Steinmetz,et al.  Melioidosis in Vietnam: Recently Improved Recognition but still an Uncertain Disease Burden after Almost a Century of Reporting , 2018, Tropical medicine and infectious disease.

[20]  S. Iamsirithaworn,et al.  Melioidosis in Thailand: Present and Future , 2018, Tropical medicine and infectious disease.

[21]  D. Limmathurotsakul,et al.  Global Burden and Challenges of Melioidosis , 2018, Tropical medicine and infectious disease.

[22]  X. Rao,et al.  Safe Staphylococcal Platform for the Development of Multivalent Nanoscale Vesicles against Viral Infections. , 2018, Nano letters.

[23]  A. Torres,et al.  Melioidosis , 1975, Nature Reviews Disease Primers.

[24]  Laura A. Muruato,et al.  Development of Subunit Vaccines That Provide High-Level Protection and Sterilizing Immunity against Acute Inhalational Melioidosis , 2017, Infection and Immunity.

[25]  W. Wiersinga,et al.  Rapid DNA vaccination against Burkholderia pseudomallei flagellin by tattoo or intranasal application , 2017, Virulence.

[26]  R. Berisio,et al.  Identification of an OmpW homologue in Burkholderia pseudomallei, a protective vaccine antigen against melioidosis. , 2016, Vaccine.

[27]  B. Wren,et al.  Intracellular replication of the well-armed pathogen Burkholderia pseudomallei. , 2016, Current opinion in microbiology.

[28]  S. Hay,et al.  Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis , 2016, Nature Microbiology.

[29]  C. Peano,et al.  Selecting soluble/foldable protein domains through single-gene or genomic ORF filtering: structure of the head domain of Burkholderia pseudomallei antigen BPSL2063. , 2015, Acta crystallographica. Section D, Biological crystallography.

[30]  D. Altmann,et al.  Consensus on the Development of Vaccines against Naturally Acquired Melioidosis , 2015, Emerging infectious diseases.

[31]  K. Vowles,et al.  Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis , 2015, Pain.

[32]  Laura A. Muruato,et al.  Recent Advances in Burkholderia mallei and B. pseudomallei Research , 2015, Current Tropical Medicine Reports.

[33]  M. Raida,et al.  Extended Loop Region of Hcp1 is Critical for the Assembly and Function of Type VI Secretion System in Burkholderia pseudomallei , 2015, Scientific Reports.

[34]  S. Nathan,et al.  Transcriptome analysis of Burkholderia pseudomallei T6SS identifies Hcp1 as a potential serodiagnostic marker. , 2015, Microbial pathogenesis.

[35]  J. Lötvall,et al.  Bacterial protoplast-derived nanovesicles as vaccine delivery system against bacterial infection. , 2015, Nano letters.

[36]  Robert Anderson,et al.  Comparison of the protective effects of killed Burkholderia pseudomallei and CpG oligodeoxynucleotide against live challenge. , 2014, Vaccine.

[37]  Nancy L Price,et al.  Production of a recombinant vaccine candidate against Burkholderia pseudomallei exploiting the bacterial N-glycosylation machinery , 2014, Front. Microbiol..

[38]  A. Torres,et al.  A Burkholderia pseudomallei Outer Membrane Vesicle Vaccine Provides Protection against Lethal Sepsis , 2014, Clinical and Vaccine Immunology.

[39]  R. M. Wooten,et al.  Development of novel O-polysaccharide based glycoconjugates for immunization against glanders , 2012, Front. Cell. Inf. Microbio..

[40]  Y. Tong,et al.  First Genome Sequence of a Burkholderia pseudomallei Isolate in China, Strain BPC006, Obtained from a Melioidosis Patient in Hainan , 2012, Journal of bacteriology.

[41]  K. Brown,et al.  A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection. , 2011, Vaccine.

[42]  I. Feavers,et al.  Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines , 2011, Expert review of vaccines.

[43]  D. DeShazer,et al.  The Cluster 1 Type VI Secretion System Is a Major Virulence Determinant in Burkholderia pseudomallei , 2011, Infection and Immunity.

[44]  K. Wan,et al.  Immunization with the recombinant Burkholderia pseudomallei outer membrane protein Omp85 induces protective immunity in mice. , 2010, Vaccine.

[45]  K. Brown,et al.  Protective response to subunit vaccination against intranasal Burkholderia mallei and B. pseudomallei challenge. , 2010, Procedia in vaccinology.

[46]  R. Titball,et al.  Protective efficacy of heat-inactivated B. thailandensis, B. mallei or B. pseudomallei against experimental melioidosis and glanders. , 2009, Vaccine.

[47]  J. Köhler,et al.  Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[48]  R. Titball Vaccines against intracellular bacterial pathogens. , 2008, Drug discovery today.

[49]  K. Brown,et al.  Identification of a LolC Homologue in Burkholderia pseudomallei, a Novel Protective Antigen for Melioidosis , 2007, Infection and Immunity.

[50]  Yin Liu,et al.  CpG-Modified Plasmid DNA Encoding Flagellin Improves Immunogenicity and Provides Protection against Burkholderia pseudomallei Infection in BALB/c Mice , 2006, Infection and Immunity.

[51]  G. Dougan,et al.  A Mutant of Burkholderia pseudomallei, Auxotrophic in the Branched Chain Amino Acid Biosynthetic Pathway, Is Attenuated and Protective in a Murine Model of Melioidosis , 2002, Infection and Immunity.

[52]  Y. Suputtamongkol,et al.  Risk factors for melioidosis and bacteremic melioidosis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.